3,874 Shares of Medpace Holdings, Inc. $MEDP Purchased by Calamos Advisors LLC

Key Points

• Calamos Advisors opened a new Medpace position, purchasing 3,874 shares valued at approximately $2.42 million in the third quarter. Institutional investors collectively own 77.98% of the stock.
• Analysts have a consensus “Hold” rating on Medpace, with a consensus price target of $649.27; three analysts rate it Buy and ten rate it Hold.
• Medpace’s latest quarterly results topped estimates: earnings were $4.84 per share versus $4.44 expected, while revenue of $716 million grew 8.5% year over year.

Calamos Advisors LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,874 shares of the company's stock, valued at approximately $2,418,000.

Several other large investors have also recently added to or reduced their stakes in MEDP. BlackRock Inc. bought a new position in shares of Medpace in the second quarter valued at approximately $1,323,047,000. State Street Corp boosted its holdings in shares of Medpace by 4.2% in the 2nd quarter. State Street Corp now owns 710,895 shares of the company's stock worth $376,483,000 after acquiring an additional 28,666 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock worth $242,337,000 after acquiring an additional 38,760 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Medpace by 5.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 395,769 shares of the company's stock worth $190,044,000 after acquiring an additional 20,736 shares during the last quarter. Finally, Madison Asset Management LLC bought a new stake in Medpace during the 2nd quarter worth approximately $128,956,000. 77.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of recent analyst reports. Weiss Ratings raised Medpace from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. Mizuho set a $730.00 price objective on Medpace in a research note on Friday, October 23rd. Robert W. Baird set a $699.00 price target on shares of Medpace in a research note on Friday, October 23rd. Royal Bank Of Canada raised their price target on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $649.27.

Insider Transactions at Medpace

In other news, General Counsel Stephen Ewald sold 1,245 shares of Medpace stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $690.00, for a total transaction of $859,050.00. Following the completion of the sale, the general counsel owned 19,098 shares in the company, valued at $13,177,620. The trade was a 6.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO August Troendle sold 21,966 shares of the business's stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the sale, the chief executive officer directly owned 338,225 shares of the company's stock, valued at approximately $211,549,590.75. This trade represents a 6.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 337,113 shares of company stock worth $210,232,507 in the last quarter. 20.50% of the stock is owned by company insiders.

Medpace Price Performance

Medpace stock opened at $653.11 on Monday. The business's 50-day simple moving average is $622.54 and its 200 day simple moving average is $532.32. The stock has a market cap of $18.27 billion, a price-to-earnings ratio of 36.20, a P/E/G ratio of 2.53 and a beta of 1.12. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $693.97.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, topping analysts' consensus estimates of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The firm had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. During the same period last year, the company earned $3.86 earnings per share. The company's revenue was up 8.5% on a year-over-year basis. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 18.06 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas.

Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.